What Does EBOS Group's(ASX:EBO) FY26 Result Signal as Its Investment Cycle Concludes?

Sonal Goyal

05 November 2026 06:16 PM AEDT

What Does EBOS Group's(ASX:EBO) FY26 Result Signal as Its Investment Cycle Concludes?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• FY26 Revenue rose 9.9% to A$13.5 billion, with Underlying EBITDA increasing 5.0% to A$614 million

• The company completed its four-year, A$360 million distribution centre renewal program during the year

• A final Dividend of NZ 61.5 cents per share was maintained, with a Payout Ratio of 84.5% of Underlying NPAT

EBOS Group(ASX:EBO) closed at A$17.40 on 05 November 2026, gaining 1.40% during the session. The S&P/ASX 200 (XJO) advanced 2.61%, adding 230.60 points to close at 9,065.10, while the S&P/ASX 200 Health Care index (XHJ) rose 3.64%, gaining 1,240.30 points to 35,329.10. Overnight Wall Street gains, buoyed by Democrats' decisive victory in the U.S. midterm elections, provided support for global equities. EBOS Group is a diversified healthcare and animal care company operating across Australia, New Zealand, and Southeast Asia, providing pharmaceutical distribution, medical devices, animal care products, and healthcare logistics.

FY26 Revenue and Earnings

On 19 August 2026, EBOS Group reported its full-year results for the period ended 30 June 2026. Revenue increased 9.9% to A$13.5 billion, supported by broad-based growth across its Healthcare and Animal Care divisions, together with contributions from recent acquisitions. Gross Operating Revenue rose 6.5% to A$1.7 billion.

Underlying EBITDA grew 5.0% to A$614 million, while Underlying NPAT declined 3.1% to A$250 million, reflecting higher Depreciation and Amortisation and financing costs associated with the Investment cycle. Statutory NPAT increased 4.7% to A$225 million. Underlying EBITDA Margin was 4.6%, down 20 basis points. The Leverage Ratio stood at 2.1x, within the company's target range of 1.7x to 2.3x, and return on Capital employed was 12.8%.

Infrastructure Program and Acquisitions

FY26 marked an important milestone for EBOS with the completion of its four-year, A$360 million distribution centre renewal program. All major facilities are now operational, with the company focused on optimisation, productivity, and growth, supporting expectations for improved free Cash Flow generation and returns on capital.

During the year, EBOS executed several strategic acquisitions including Paringa Pet Foods and K-Talyst, further expanding capabilities in higher-growth, higher-return markets. CEO Adam Hall noted that the company is moving beyond peak Capital Investment and entering FY27 with a portfolio positioned for lower capital intensity and capacity to invest in future growth.

About EBOS Group

EBOS Group is one of the largest and most diversified healthcare and animal care companies in the Australasian region. The company distributes pharmaceuticals and medical devices, provides contract logistics for healthcare manufacturers, and operates a growing animal care division. Listed on both the NZX and ASX, EBOS serves hospitals, pharmacies, veterinary clinics, and retail channels across its operating geographies.

Sector Context

The ASX healthcare sector broadly advanced on 05 November 2026, outperforming the benchmark index. Healthcare distribution businesses in Australia continue to benefit from an ageing population and growing pharmaceutical volumes, while animal care remains a structural growth category driven by pet ownership trends and premiumisation.

Risks

Risks facing EBOS include exposure to regulatory changes affecting pharmaceutical distribution margins and government pricing policies. Elevated fuel and energy costs affected FY26 results and could persist. The company carries Acquisition integration risk, and its leverage ratio, while within target, limits headroom for further capital deployment. Foreign exchange movements also present a risk given the company's cross-border operations.

Catalysts on Watch

The market will monitor whether the completion of the distribution centre program translates into the anticipated improvement in free cash flow and returns. The integration and performance of recent acquisitions, progress on growth initiatives outlined at the Investor Day, and any further M&A activity are additional catalysts. FY27 EBITDA growth guidance and the trajectory of the leverage ratio will also draw attention.

The Path Forward

EBOS Group's FY26 result represents a transitional year, with the company completing its largest infrastructure investment program and positioning for the next phase of growth. With lower capital intensity ahead and a diversified Earnings base spanning healthcare and animal care, management has expressed confidence in the company's ability to deliver continued EBITDA growth and improved returns for shareholders.

FAQs

Q: What was EBOS Group's FY26 revenue?

A: FY26 revenue was A$13.5 billion, an increase of 9.9% on the prior year.

Q: What was the Underlying EBITDA for FY26?

A: Underlying EBITDA grew 5.0% to A$614 million.

Q: What infrastructure program did EBOS complete in FY26?

A: EBOS completed its four-year, A$360 million distribution centre renewal program, with all major facilities now operational.

Q: What was EBOS Group's dividend for FY26?

A: The final dividend was maintained at NZ 61.5 cents per share, with a payout ratio of 84.5% of Underlying NPAT.

Q: What acquisitions did EBOS make during FY26?

A: EBOS executed acquisitions including Paringa Pet Foods and K-Talyst during FY26, expanding capabilities in higher-growth markets.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.